Clinical Trial Update: Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing the safety, tolerability, and treatment response study of GXV813 in hospitalized adults with schizophrenia, currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• GXV813

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING